At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 623 enrolled
Drug / intervention
SNG001 +1 moredrug
Likely dose
SNG001 0.65 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Placebo-controlled, Phase III Trial to Determine the Efficacy and Safety of Inhaled SNG001 for the Treatment of Patients Hospitalised Due to Moderate COVID-19
In Brief
A Phase 3 clinical trial evaluating SNG001 and Placebo for Severe Acute Respiratory Syndrome Coronavirus 2 and COVID-19. Completed, enrolled 623 participants across 112 sites in 17 countries.
Detailed Summary
The purpose of this Phase III study is to confirm that SNG001 can accelerate the recovery of hospitalised patients receiving oxygen with confirmed Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Safety and other efficacy endpoints will also be assessed.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Belgium, Brazil, Colombia, France, Germany, India, Israel, Italy, Mexico, Netherlands, Portugal, Romania, Serbia, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
Enrollment StartJan 2021
First PostedFeb 2021
Primary CompletionDec 2021
Study CompletionFeb 2022
TodayJul 2026
First PostedFeb 1, 2021
Enrollment StartJan 12, 2021
Primary CompletionDec 15, 2021
Study CompletionFeb 10, 2022
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 5.4 years ago
Interventions
SNG001drug
SNG001 nebuliser solution, 2 syringes each containing 0.65 mL once a day
Placebodrug
Placebo nebuliser solution, 2 syringes each containing 0.65 mL solution containing excipients of the SNG001 solution